We are actively seeking strategic collaborations and licensing opportunities that align with our therapeutic areas of focus.
To explore partnership opportunities, please contact us.
Kiryat Atidim, Building 7
Tel Aviv, Israel 6158002
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in late 2022.
Copyright © Chemomab. All rights reserved. Privacy Policy. Terms of Use.
Site Design by Michael Kulwiec DesignLab.
